Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-α

Giuseppe Derosa, Arrigo F G Cicero, Angela D'Angelo, Pietro D. Ragonesi, Leonardina Ciccarelli, Mario N. Piccinni, Fabio Pricolo, Sibilla A T Salvadeo, ILaria Ferrari, Alessia Gravina, Roberto Fogari

Research output: Contribution to journalArticle

Abstract

The aim of our study was to investigate the metabolic effect of telmisartan and irbesartan in subjects treated with rosiglitazone, a well-known insulin-sensitizing drug, in order to clarify the direct metabolic effects of the two former drugs. Patients were enrolled, evaluated, and followed at 3 Italian centers. We evaluated 188 type 2 diabetic patients with metabolic syndrome (94 males and 94 females in total; 49 males and 46 females, aged 56±5, treated with telmisartan; and 45 males and 48 females, aged 55±4, treated with irbesartan). All had been diabetic for at least 6 months, and glycemic control by the maximum tolerated dietary changes and maximum tolerated dose of oral hypoglycemic agents had been attempted and failed in all cases. All patients took a fixed dose of rosiglitazone, 4 mg/day. We administered telmisartan (40 mg/day) or irbesartan (150 mg/day) in a randomized, controlled, double-blind clinical manner. We evaluated body mass index (BMI), glycemic control (HbA1c, fasting plasma glucose and insulin levels [FPG, and FPI, respectively], and homeostasis model assessment [HOMA] index), lipid profile (total cholesterol [TC], low density lipoprotein-cholesterol [LDL-C], high density lipoprotein-cholesterol [HDL-C], and triglycerides [TG]), systolic and diastolic blood pressure (SBP and DBP), tumor necrosis factor-α (TNF-α), and leptin during the 12 months of this treatment. No BMI change was observed after 6 or 12 months in either group. Significant decreases in HbA1c and FPG were observed after 6 months in the telmisartan group, and after 12 months in both groups. The decrease in HbA1c and FPG at 12 months was statistically significant only in the telmisartan group. A significant decrease in FPI was observed at 12 months in both groups, and this decrease was significantly greater in the telmisartan group. Significant decreases in the HOMA index were observed at 6 and 12 months in both groups, and the decrease in the HOMA index after 12 months was significantly greater in the telmisartan group than in the irbesartan group. Significant changes in SBP, DBP, TC, and LDL-C were observed after 6 and 12 months in both groups. Significant decreases in TNF-α and leptin levels were observed after 6 months in the telmisartan group, and after 12 months in both groups. In conclusion, in this study of patients with type 2 diabetes mellitus and metabolic syndrome, telmisartan seemed to result in a greater improvement in glycemic and lipid control and metabolic parameters related to metabolic syndrome compared to irbesartan. These observed metabolic effects of different angiotensin type 1 receptor blockers could be relevant when choosing a therapy to correct metabolic derangement of patients affected by metabolic syndrome and diabetes.

Original languageEnglish
Pages (from-to)849-856
Number of pages8
JournalHypertension Research
Volume29
Issue number11
DOIs
Publication statusPublished - Nov 2006

Keywords

  • Irbesartan
  • Metabolic syndrome
  • Rosiglitazone
  • Telmisartan
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-α'. Together they form a unique fingerprint.

  • Cite this

    Derosa, G., Cicero, A. F. G., D'Angelo, A., Ragonesi, P. D., Ciccarelli, L., Piccinni, M. N., Pricolo, F., Salvadeo, S. A. T., Ferrari, IL., Gravina, A., & Fogari, R. (2006). Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertension Research, 29(11), 849-856. https://doi.org/10.1291/hypres.29.849